- Joined
- Feb 3, 2007
- Messages
- 873
- Reaction score
- 3
NanoDrugDelivery.net
Moniker until 3/3/09
Only $60!!
Just one example of how the technology can be used.
From "nano markets", a research firm:
According to a newly released report from NanoMarkets, an industry consulting firm based here, nanotechnology-enabled drug delivery systems will generate over $1.7 billion ($US) in 2009 and over $4.8 billion in 2012.
NanoMarkets key findings in this report include the following:
Nano-enabled drug delivery systems will allow for reformulations which will protect patent holders against generic competing products and help firms boost profits, a key issue in the drug industry today, which is suffering from high R&D costs and a scarcity of blockbuster drugs.
Oral delivery of active compounds is, and is expected to remain, the primary means of administering drugs for the pharmaceutical industry. NanoMarkets believes that the largest portion of nanotechnology R&D funding will be used in development of these types of systems and that this will be one of the big success stories in nanotechnology-enabled drug delivery.
Nano-enabled polymeric delivery systems account for the single largest market opportunity, as projected by NanoMarkets. This conclusion is based on some of the early successes experienced by companies such as Elan Pharmaceuticals (which already has several products on the market), as well as feedback from large pharmaceutical companies that are investing heavily in this segment.
Imaging agents will become one of the most lucrative applications in nano- enabled drug delivery. The industry has been rapidly adopting biomarkers and pharmacogenomic testing regimens into drug discovery and delivery, which may speed time-to- market and enhance clinical evidence of a compounds efficacy.
Moniker until 3/3/09
Only $60!!
Just one example of how the technology can be used.
From "nano markets", a research firm:
According to a newly released report from NanoMarkets, an industry consulting firm based here, nanotechnology-enabled drug delivery systems will generate over $1.7 billion ($US) in 2009 and over $4.8 billion in 2012.
NanoMarkets key findings in this report include the following:
Nano-enabled drug delivery systems will allow for reformulations which will protect patent holders against generic competing products and help firms boost profits, a key issue in the drug industry today, which is suffering from high R&D costs and a scarcity of blockbuster drugs.
Oral delivery of active compounds is, and is expected to remain, the primary means of administering drugs for the pharmaceutical industry. NanoMarkets believes that the largest portion of nanotechnology R&D funding will be used in development of these types of systems and that this will be one of the big success stories in nanotechnology-enabled drug delivery.
Nano-enabled polymeric delivery systems account for the single largest market opportunity, as projected by NanoMarkets. This conclusion is based on some of the early successes experienced by companies such as Elan Pharmaceuticals (which already has several products on the market), as well as feedback from large pharmaceutical companies that are investing heavily in this segment.
Imaging agents will become one of the most lucrative applications in nano- enabled drug delivery. The industry has been rapidly adopting biomarkers and pharmacogenomic testing regimens into drug discovery and delivery, which may speed time-to- market and enhance clinical evidence of a compounds efficacy.
